3 completed, 2 terminated. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 2 | 2 | Terminated 2 |
Follow PR-104: new trials by email Literature Review of PR-104 trials Research Report on PR-104
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) PR104 550 mg/m^2 + sorafenib, PR104 770 mg/m^2 + sorafenib - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Terminated | Proacta, Incorporated | 14 | 2009-03-01 | 2013-08-23 |
| PR104 and G-CSF in Treating Patients With Solid Tumors filgrastim, PR104, F-18-fluoromisonidazole - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Proacta, Incorporated | 5 | 2008-02-01 | 2011-06-01 |
| PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer PR104, F-18-fluoromisonidazole - Lung Cancer | Phase 2 | Terminated | Proacta, Incorporated | 5 | 2007-08-01 | 2012-12-10 |
| PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors PR-104, docetaxel, gemcitabine hydrochloride - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Proacta, Incorporated | 42 | 2007-02-01 | 2011-03-02 |
| PR-104 in Treating Patients With Advanced Solid Tumors PR-104, laboratory biomarker analysis, pharmacological study - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Proacta, Incorporated | 27 | 2005-12-01 | 2012-11-30 |
Carcinoma, Hepatocellular (1) · Lung Neoplasms (1) · Small Cell Lung Carcinoma (1)
United States (5) · New Zealand (2) · Hong Kong (1) · Singapore (1) · Taiwan (1)
Mark D. Pegram, MD (1) · Terri J. Melink, NP, MSN, ANP (1)
P30CA016042 (1)